Evaluation of the Safety and Effectiveness of Nevirapine Plus Coformulated Tenofovir/Emtricitabine as First-Line Therapy in Routine Clinical Practice
- 1 February 2012
- journal article
- research article
- Published by SAGE Publications in AIDS Research and Human Retroviruses
- Vol. 28 (2) , 165-170
Abstract
Despite having demonstrated noninferior efficacy against atazanavir/ritonavir plus coformulated tenofovir/emtricitabine (cTDF/FTC), the combination of nevirapine plus cTDF/FTC is not included among preferred regimens in some international guidelines. This combination is frequently used in Spain. We analyzed its effectiveness and safety as first-line therapy in a routine clinical practice. A retrospective, multicenter study was performed in treatment-naive HIV-1-infected subjects who started nevirapine plus cTDF/FTC as first-line therapy according to the nevirapine CD4+ cell count threshold. The primary endpoint was the proportion of subjects with plasma HIV-1 RNA + cell count was 215 cells/μl, the median plasma viral load (VL) was 4.83 log10 copies/ml, and 22% had hepatitis C coinfection. At week 48, 96 subjects (78%; 95% CI: 69.9–84.4) had a VL + cell count was 118 cells/μl. Virological failure was observed in 6.5% (8/123) of subjects, all them before week 24 and related to poor adherence. There was no relationship between virological failure and baseline CD4+ cell count or VL. Ten percent (13/123) of the subjects discontinued the treatment due to adverse events. There was a significant decrease in total/HDL-cholesterol ratio (p=0.03) with an increase in HDL-cholesterol (p=0.01) over 48 weeks. The combination of nevirapine plus cTDF/FTC showed a high virological efficacy without unexpected toxicities as a first-line treatment in a routine clinical practice.Keywords
This publication has 23 references indexed in Scilit:
- Atazanavir Plus Ritonavir or Efavirenz as Part of a 3-Drug Regimen for Initial Treatment of HIV-1Annals of Internal Medicine, 2011
- Antiretroviral Treatment of Adult HIV InfectionJAMA, 2010
- Nevirapine versus Atazanavir/Ritonavir, Each Combined with Tenofovir Disoproxil Fumarate/Emtricitabine, in Antiretroviral-Naive HIV-1 Patients: The Arten TrialAntiviral Therapy, 2010
- Once-Daily Atazanavir/Ritonavir Compared With Twice-Daily Lopinavir/Ritonavir, Each in Combination With Tenofovir and Emtricitabine, for Management of Antiretroviral-Naive HIV-1–Infected Patients: 96-Week Efficacy and Safety Results of the CASTLE StudyJAIDS Journal of Acquired Immune Deficiency Syndromes, 2010
- Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trialThe Lancet, 2009
- Once-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysisAIDS, 2009
- High rate of early virological failure with the once-daily tenofovir/lamivudine/nevirapine combination in naive HIV-1-infected patientsJournal of Antimicrobial Chemotherapy, 2008
- Class-Sparing Regimens for Initial Treatment of HIV-1 InfectionNew England Journal of Medicine, 2008
- Risk of Early Virological Failure of Once‐Daily Tenofovir‐Emtricitabine plus Twice‐Daily Nevirapine in Antiretroviral Therapy–Naive HIV‐Infected PatientsClinical Infectious Diseases, 2008
- Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN StudyThe Lancet, 2004